These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
62135-0312 Market Analysis and Financial Projection
The NDC 62135-0312 corresponds to Anagrelide Hydrochloride, a prescription medication used to treat thrombocytosis (excessive platelet production). Below is a market analysis and price projection based on available data:
Current Market Overview
Anagrelide Hydrochloride is approved under ANDA 087294 and marketed by Chartwell RX, LLC, as a generic drug. It falls under the Human Prescription Drug category and is typically administered in 0.5 mg oral capsules[1][11].
Pricing (2024–2025):
Average price per unit: $11.16 (consistent across distributors like Chartwell RX and Torrent Pharmaceuticals)[9][10].
Market Position:
As a generic drug for a rare blood disorder, Anagrelide competes with brands like Agrylin. The market is niche, with limited manufacturers, reducing price volatility[11][12].
Price Projections and Trends
Short-Term (2025–2027):
Prices are expected to remain stable at $11.00–$11.50/unit due to consistent manufacturing costs and generic competition[9][10].
The current 8.1% CAGR in clinical trial archiving solutions (which include drug storage logistics) may indirectly support stable supply chains, preventing price spikes[2].
Long-Term (2028–2030):
Anticipated 3–4% annual price increase, aligning with broader pharmaceutical market trends (e.g., the Imatinib market’s 3% CAGR)[8].
Macroeconomic resilience and potential rate cuts impacting production expenses[4].
Competitive Landscape
Key Players: Chartwell RX, Torrent Pharmaceuticals, and Teva Pharmaceuticals[9][10].
Differentiation: Limited innovation in this niche segment, with most growth tied to volume expansion in rare-disease therapeutics.
Key Risks
Regulatory Scrutiny: Stricter GDP/GTP compliance could raise operational costs[2].
Generic Saturation: New entrants may drive price reductions post-2030[8][10].
Highlight: “Generic drugs in niche therapeutic areas like thrombocytosis often exhibit pricing stability due to predictable demand and limited competition.” [8][12]
Key Takeaways
Stable short-term pricing at ~$11.16/unit with moderate long-term growth.
Market resilience tied to rare-disease treatment demand and regulatory dynamics.
FAQs
What is Anagrelide Hydrochloride used for?
It reduces platelet production in conditions like essential thrombocythemia[11].
Why are prices projected to rise post-2027?
Inflation and compliance costs outweigh generic competition effects[2][4].
Who are the main distributors?
Chartwell RX, Torrent Pharmaceuticals, and Teva[9][10].
For real-time updates, consult DrugPatentWatch or FDA NDC Directory[1][5].
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
